The FDA approved Prevduo for use in adults and children at least 2 years old to help regain muscle function after surgery.

The FDA granted approval to Altuviiio as a first-in-class, high-sustained factor VIII replacement therapy for hemophilia A patients on February 22, 2023.

The FDA granted accelerated approval to Sparsentan for its ability to reduce proteinuria (excess protein in the urine) in adults with primary immunoglobulin A nephropathy.

Pirtobrutinib, marketed under the brand name Jaypirca, is FDA approved. The FDA granted accelerated approval to Pirtobrutinib on January 27, 2023.

Elacestrant was approved by the FDA on January 27, 2023, for the treatment of advanced or metastatic breast cancer in postmenopausal women and adult men.

The FDA approved Bexagliflozin under the brand name Brenzavvy on January 20, 2023.

The FDA approved the combination of albuterol and budesonide under the brand name Airsupra on January 10, 2023.

Lecanemab, marketed under the brand name Leqembi, was granted accelerated approval by the FDA on January 6, 2023.

Ublituximab, marketed under the brand name Briumvi, is a CD20 monoclonal antibody used in the treatment of multiple sclerosis (MS). Ublituximab was approved by the FDA on December 28, 2022.

Xenoview received FDA approval on December 23, 2022. It plays a crucial role in providing clearer images of certain areas of the body, particularly the lungs, without the need for radiation exposure.

Adstiladrin received FDA approval on December 16, 2022. It represents a significant advancement in cancer therapy, particularly for patients who have not responded to standard treatments.

Adagrasib, marketed under the brand name Krazati, is an oral medication used to treat adults with non-small cell lung cancer (NSCLC).